Immunological targeting of cytomegalovirus for glioblastoma therapy

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Nair, Smita K ^a   Sampson, John H ^a   Mitchell, Duane A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Glioblastoma; Immunotherapy; RNA transfected dendritic cells

Indexed keywords

CANCER VACCINE; CYTOMEGALOVIRUS ANTIGEN PP65; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CYTOMEGALOVIRUS; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; NONHUMAN; PROTEIN TARGETING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS DETECTION;

EID: 84906516244     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29289     Document Type: Article

References (10)

1. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62:3347-50; PMID:12067971
2. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10:10-8; PMID:17951512; http:// dx.doi.org/10.1215/15228517-2007-035
3. Cobbs CS. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol 2013; 25:682-8; PMID:24097102; http://dx.doi.org/10.1097/ CCO.0000000000000005
4. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, Liu R, Johnson LA, Weinhold K, Archer GE, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res 2014; 20:2684-94; PMID:24658154; http://dx.doi.org/10.1158/1078-0432.CCR-13-3268
5. Nair S, Archer GE, Tedder TF. Isolation and generation of human dendritic cells. Curr Protoc Immunol. 2012;Chapter 7:Unit7 32.
6. Nair S, Boczkowski D. RNA-transfected dendritic cells. Expert Rev Vaccines 2002; 1:507-13; PMID:12901589; http://dx.doi. org/10.1586/14760584.1.4.507
7. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http:// dx.doi.org/10.1038/79519
8. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol 2012; 90:872-80; PMID:22508289; http:// dx.doi.org/10.1038/icb.2012.19
9. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, et al. Generation of polyclonal CMVspecific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012; 35:159-68; PMID:22306904; http://dx.doi.org/10.1097/ CJI.0b013e318247642f
10. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, et al. Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma. Cancer Res 2014; 74:3466-76.; PMID:24795429; http://dx.doi.org/10.1158/0008-5472.CAN-14-0296